348 related articles for article (PubMed ID: 25737278)
1. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.
Guillemette S; Serra RW; Peng M; Hayes JA; Konstantinopoulos PA; Green MR; Cantor SB
Genes Dev; 2015 Mar; 29(5):489-94. PubMed ID: 25737278
[TBL] [Abstract][Full Text] [Related]
2. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer.
Hou MF; Luo CW; Chang TM; Hung WC; Chen TY; Tsai YL; Chai CY; Pan MR
Exp Cell Res; 2017 Oct; 359(2):458-465. PubMed ID: 28842166
[TBL] [Abstract][Full Text] [Related]
3. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
Oyama Y; Shigeta S; Tokunaga H; Tsuji K; Ishibashi M; Shibuya Y; Shimada M; Yasuda J; Yaegashi N
PLoS One; 2021; 16(6):e0251079. PubMed ID: 34161330
[TBL] [Abstract][Full Text] [Related]
4. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Sakai W; Swisher EM; Karlan BY; Agarwal MK; Higgins J; Friedman C; Villegas E; Jacquemont C; Farrugia DJ; Couch FJ; Urban N; Taniguchi T
Nature; 2008 Feb; 451(7182):1116-20. PubMed ID: 18264087
[TBL] [Abstract][Full Text] [Related]
5. CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes.
Xia L; Huang W; Bellani M; Seidman MM; Wu K; Fan D; Nie Y; Cai Y; Zhang YW; Yu LR; Li H; Zahnow CA; Xie W; Chiu Yen RW; Rassool FV; Baylin SB
Cancer Cell; 2017 May; 31(5):653-668.e7. PubMed ID: 28486105
[TBL] [Abstract][Full Text] [Related]
6. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract][Full Text] [Related]
7. Resistance to therapy caused by intragenic deletion in BRCA2.
Edwards SL; Brough R; Lord CJ; Natrajan R; Vatcheva R; Levine DA; Boyd J; Reis-Filho JS; Ashworth A
Nature; 2008 Feb; 451(7182):1111-5. PubMed ID: 18264088
[TBL] [Abstract][Full Text] [Related]
8. CHD4 regulates the DNA damage response and RAD51 expression in glioblastoma.
McKenzie LD; LeClair JW; Miller KN; Strong AD; Chan HL; Oates EL; Ligon KL; Brennan CW; Chheda MG
Sci Rep; 2019 Mar; 9(1):4444. PubMed ID: 30872624
[TBL] [Abstract][Full Text] [Related]
9. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
Sakai W; Swisher EM; Jacquemont C; Chandramohan KV; Couch FJ; Langdon SP; Wurz K; Higgins J; Villegas E; Taniguchi T
Cancer Res; 2009 Aug; 69(16):6381-6. PubMed ID: 19654294
[TBL] [Abstract][Full Text] [Related]
10. The epigenetic factor CHD4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer.
Wang J; Zhong F; Li J; Yue H; Li W; Lu X
J Transl Med; 2023 Jan; 21(1):38. PubMed ID: 36681835
[TBL] [Abstract][Full Text] [Related]
11. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
12. The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage.
Larsen DH; Poinsignon C; Gudjonsson T; Dinant C; Payne MR; Hari FJ; Rendtlew Danielsen JM; Menard P; Sand JC; Stucki M; Lukas C; Bartek J; Andersen JS; Lukas J
J Cell Biol; 2010 Sep; 190(5):731-40. PubMed ID: 20805324
[TBL] [Abstract][Full Text] [Related]
13. CHD4 in the DNA-damage response and cell cycle progression: not so NuRDy now.
O'Shaughnessy A; Hendrich B
Biochem Soc Trans; 2013 Jun; 41(3):777-82. PubMed ID: 23697937
[TBL] [Abstract][Full Text] [Related]
14. Association of the chromodomain helicase DNA-binding protein 4 (CHD4) missense variation p.D140E with cancer: potential interaction with smoking.
Yamada M; Sato N; Ikeda S; Arai T; Sawabe M; Mori S; Yamada Y; Muramatsu M; Tanaka M
Genes Chromosomes Cancer; 2015 Feb; 54(2):122-8. PubMed ID: 25407497
[TBL] [Abstract][Full Text] [Related]
15. Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.
Sperlazza J; Rahmani M; Beckta J; Aust M; Hawkins E; Wang SZ; Zu Zhu S; Podder S; Dumur C; Archer K; Grant S; Ginder GD
Blood; 2015 Sep; 126(12):1462-72. PubMed ID: 26265695
[TBL] [Abstract][Full Text] [Related]
16. The role of DNA repair pathways in cisplatin resistant lung cancer.
O'Grady S; Finn SP; Cuffe S; Richard DJ; O'Byrne KJ; Barr MP
Cancer Treat Rev; 2014 Dec; 40(10):1161-70. PubMed ID: 25458603
[TBL] [Abstract][Full Text] [Related]
17. CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK/ERK axis.
Wu J; Zhou Z; Li J; Liu H; Zhang H; Zhang J; Huang W; He Y; Zhu S; Huo M; Liu M; Zhang C
Drug Resist Updat; 2023 Jan; 66():100913. PubMed ID: 36603431
[TBL] [Abstract][Full Text] [Related]
18. CHD4 as an important mediator in regulating the malignant behaviors of colorectal cancer.
Chang CL; Huang CR; Chang SJ; Wu CC; Chen HH; Luo CW; Yip HK
Int J Biol Sci; 2021; 17(7):1660-1670. PubMed ID: 33994851
[TBL] [Abstract][Full Text] [Related]
19. [Expression of DNA transcription- and repair-related genes in cisplatin-resistant human ovarian carcinoma cell line COC1/DDP].
Cao MM; Zhang JR; Wang SM; Hu XG; Hu LJ
Di Yi Jun Yi Da Xue Xue Bao; 2005 Dec; 25(12):1478-81. PubMed ID: 16354609
[TBL] [Abstract][Full Text] [Related]
20. Tumour-associated missense mutations in the dMi-2 ATPase alters nucleosome remodelling properties in a mutation-specific manner.
Kovač K; Sauer A; Mačinković I; Awe S; Finkernagel F; Hoffmeister H; Fuchs A; Müller R; Rathke C; Längst G; Brehm A
Nat Commun; 2018 May; 9(1):2112. PubMed ID: 29844320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
